DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Filorexant
Filorexant
Filorexant | Medchemexpress
Preventive Report Appendix
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Perspective Rxpipeline a Pharmacy
Clinical Pharmacology of Daridorexant, a Novel Dual Orexin Receptor Antagonist
G Protein-Coupled Receptors
G Protein‐Coupled Receptors
IJBCP International Journal of Basic & Clinical Pharmacology Orexin
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Laszlo Vecsei-MS
Nuevos Tratamientos Contra La Migraña
The Use of Physiology-Based PK and PD Modeling in the Discovery of the Dual
Analysis of Plasma Orexin Levels in Pedıatrıc Migraine Patients: a Prospectıve Controlled Clinical Study
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Migraine Headache
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
K K Neurobiological Basis of Migraine
Top View
Dual'' Orexin Receptor Antagonists at OX1R and OX2R Orexin Receptors
Studies Toward the Synthesis of a Novel Diamine Scaffold
Study Protocol and All Previous Versions Are Provided on the Following Pages
Kinetic Properties of "Dual'' Orexin Receptor Antagonists at OX1R And
Recent Advances in Migraine Therapy Fabio Antonaci1,2*, Natascia Ghiotto1, Shizheng Wu3, Ennio Pucci1,2 and Alfredo Costa1,2
Targeted Orexin and Hypothalamic Neuropeptides for Migraine
Emerging Drugs for Migraine Treatment: an Update
Review Article “Recent Advances in Drug Therapy Of
A Novel Dual Orexin Receptor Antagonist S
Rôle Antitumoral De L'orexine a Et Des Ligands Biaisés Dans Les Cancers Digestifs
Insomnia in Elderly Patients: Recommendations for Pharmacological Management
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
G Protein-Coupled Receptors
G Protein-Coupled Receptors
An Update on Migraine: Current Understanding and Future Directions
Endocrinology
The Use of Physiology-Based PK and PD Modeling in the Discovery of the Dual
Phase II Proof-Of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder Kathryn M